Clinical trials
Recherche d’études cliniques
Recherchez uniquement dans les études cliniques enregistrées dans Biomedical Watch.
Études cliniques 612
| Étude / NCT ⇅ | Molécule ⇅ | Maladie ⇅ | Phase ⇅ | Statut ⇅ | Résultat ⇅ | Sponsor ⇅ | Pays / centres ⇅ | Période ⇅ | Détail |
|---|---|---|---|---|---|---|---|---|---|
| NCT05532943 UMSC01 — Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord … |
Allogeneic umbilical cord mesench… | SEP | Phase 1/2 | RECRUITING | En attente / non publié | Ever Supreme Bio Technology Co., … | Taiwan · China Medical University Hospital, Taichung,… | 2023-09-08 → 2028-10-31 | Ouvrir |
| NCT00559702 Safety Study of Natalizumab to Treat Multiple Sclerosis (MS) |
natalizumab | SEP | Phase 1 | COMPLETED | En attente / non publié | Biogen | United States · Research Site, Berkeley, United State… | 2007-10 → 2011-11 | Ouvrir |
| NCT03774407 Vaginal Estriol in Multiple Sclerosis |
vaginal estriol | SEP | Phase 2/3 | COMPLETED | En attente / non publié | Texas Tech University Health Scie… | United States · Texas Tech University Health Sciences… | 2019-06-20 → 2020-11-29 | Ouvrir |
| NCT01220830 RFQMR — Cytotron® Delivered Rotational Field Quantum Nuclear Magnetic R… |
Cytotron | SEP | Phase 2 | UNKNOWN | En attente / non publié | The Centre for Advanced Research … | India · Centre for Advanced Research and Development,… | 2010-09 → 2011-12 | Ouvrir |
| NCT04909502 Evaluation of Safety, Tolerability and Preliminary Efficacy of EHP-101 … |
EHP-101 25 mg OD | SEP | Phase 2 | SUSPENDED | En attente / non publié | Emerald Health Pharmaceuticals | United States, Australia · Accel Research Sites - Bra… | 2021-10-19 → 2024-04 | Ouvrir |
| NCT01808885 MSREPAIR — Safety Study of Olesoxime in Patients With Stable Relapsing … |
olesoxime (TRO19622) | SEP | Phase 1 | COMPLETED | En attente / non publié | Hoffmann-La Roche | France · CHU Pontchaillou, Neurology Department, Renn… | 2013-04 → 2014-01 | Ouvrir |
| NCT01244139 Safety Study of BIIB033 in Subjects With Multiple Sclerosis |
BIIB033 | SEP | Phase 1 | COMPLETED | En attente / non publié | Biogen | United States · Research Site, Centennial, United Sta… | 2010-10 → 2012-04 | Ouvrir |
| NCT02087631 Safety and Tolerability of Quetiapine in Multiple Sclerosis |
Extended-release quetiapine fumar… | SEP | Phase 1/2 | COMPLETED | En attente / non publié | University of Calgary | Canada · MS Clinic, Foothills Medical Centre, Calgary… | 2014-12 → 2019-07 | Ouvrir |
| NCT02649985 MAPET — PET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, a… |
[F-18]PBR06 | SEP | Phase 1/2 | RECRUITING | En attente / non publié | Brigham and Women's Hospital | United States · Brigham MS Center, 60 Fenwood Road, B… | 2016-05-02 → 2027-12-31 | Ouvrir |
| NCT04626921 VISIONMS-LTE — A Multi-Center, Open-Label Long-Term Extension Study of … |
CNM-Au8 | SEP | Phase 2/3 | COMPLETED | En attente / non publié | Clene Nanomedicine | Australia · John Hunter Hospital, New Lambton Heights… | 2020-10-22 → 2023-09-06 | Ouvrir |
| NCT05834855 Noisy Rebels — Non-inferiority Study of Rituximab Compared to Ocrelizum… |
Rituximab | SEP | Phase 3 | RECRUITING | En attente / non publié | National Cancer Institute (NCI) | Netherlands · Amsterdam UMC, location VUmc, Amsterdam… | 2023-04 → 2027-05 | Ouvrir |
| NCT02545868 A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In P… |
23-PPV | SEP | Phase 3 | COMPLETED | En attente / non publié | Hoffmann-La Roche | United States, Canada · Abington Neurological Associa… | 2015-10-27 → 2021-09-21 | Ouvrir |
| NCT06586177 REBELLION-MS — Understanding the 'Durable Effect' Concept of B-cell Mod… |
Anti-CD20 antibody | SEP | À vérifier | RECRUITING | En attente / non publié | Heinrich-Heine University, Duesse… | Germany · Heinrich-Heine University, Duesseldorf, Düs… | 2021-10-27 → 2028-12-31 | Ouvrir |
| NCT05266469 Exploring the Profiles of RMS Patients on Ofatumumab or Ocrelizumab in … |
Exploring the Profiles of RMS Pat… | SEP | À vérifier | COMPLETED | En attente / non publié | Novartis Pharmaceuticals | United Arab Emirates · Novartis Investigative Site, A… | 2022-07-26 → 2024-11-11 | Ouvrir |
| NCT07256704 HYPNOVA — Hypnosis and Attention in Patients With a Neurological Diseas… |
HYPNOVA — Hypnosis and Attention … | SEP | Non applicable | RECRUITING | En attente / non publié | Luzerner Kantonsspital | Switzerland · Luzerner Kantonsspital, Lucerne, Switze… | 2025-11-18 → 2029-07-31 | Ouvrir |
| NCT05958381 MS-HDtDCS — Treatment of Cognitive Deficits in Multiple Sclerosis With … |
Transcranial Direct Current stimu… | SEP | Non applicable | RECRUITING | En attente / non publié | Dr. Ram Manohar Lohia Hospital | United States · The University of Texas at Dallas, Ri… | 2023-10-18 → 2027-06-29 | Ouvrir |
| NCT07766213 Pain Phenotypes in Individuals With Multiple Sclerosis |
Pain Phenotypes in Individuals Wi… | SEP | À vérifier | NOT_YET_RECRUITING | En attente / non publié | Kutahya Health Sciences University | Turkey (Türkiye) · Kutahya Health Sciences University… | 2026-08-15 → 2027-09-15 | Ouvrir |
| NCT07765212 INDAMS — Evaluating the Use of Oral Indapamide to Reduce Disabiltiy Pro… |
Indapamide | SEP | Phase 2 | NOT_YET_RECRUITING | En attente / non publié | Eva M.M. Strijbis | Non communiqué | 2026-09 → 2028-09 | Ouvrir |
| NCT07325292 Frexcite — Non-inferiority Study of Frexalimab Subcutaneous Administrat… |
Frexalimab | SEP | Phase 3 | RECRUITING | En attente / non publié | Sanofi | United States, Belgium, China, Italy, Japan · Advance… | 2026-01-14 → 2028-11-30 | Ouvrir |
| NCT03437473 Safety and Efficacy of Vagus Nerve Stimulator in Patients With Rheumato… |
SetPoint Medical Neurostimulation… | SEP | Non applicable | COMPLETED | En attente / non publié | SetPoint Medical Corporation | United States · Altoona Center for Clinical Research,… | 2018-03-06 → 2018-12-10 | Ouvrir |
| NCT07489326 ACTIVATE — The SetPoint System Safety & Performance Post-Approval Study |
SetPoint System | SEP | À vérifier | NOT_YET_RECRUITING | En attente / non publié | SetPoint Medical Corporation | Non communiqué | 2026-04-15 → 2031-01-01 | Ouvrir |
| NCT04862117 Long Term Extension of Safety and Efficacy of Vagus Nerve Stimulator in… |
SetPoint Medical Neurostimulation… | SEP | Non applicable | ACTIVE_NOT_RECRUITING | En attente / non publié | SetPoint Medical Corporation | United States · Altoona Center for Clinical Research,… | 2018-07-28 → 2026-12-08 | Ouvrir |
| NCT04539964 RESET-RA — Vagus Nerve Stimulation for Moderate to Severe Rheumatoid Ar… |
Implant Procedure | SEP | Phase 3 | ACTIVE_NOT_RECRUITING | En attente / non publié | SetPoint Medical Corporation | United States · Albuquerque Center For Rheumatology, … | 2021-01-11 → 2027-10 | Ouvrir |
| NCT07337785 CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Dis… |
CD19/BCMA-targeted CAR-T cells | Myasthénie | Phase 1 | RECRUITING | En attente / non publié | Tongji Hospital | China · Tongji Hospital, Tongji Medical College, Huaz… | 2025-12-12 → 2028-11-01 | Ouvrir |
| NCT07753122 ME/CFS — Controlled Trial of Hydrogen Water as a Treatment for Myalgic … |
ME/CFS — Controlled Trial of Hydr… | Myopathies | Non applicable | RECRUITING | En attente / non publié | Fred Friedberg | United States · Stony Brook University, Stony Brook, … | 2026-08-15 → 2027-07 | Ouvrir |